217 related articles for article (PubMed ID: 21867480)
1. The role of estrogen and estrogen receptors in chemoresistance.
Sui M; Zhang H; Fan W
Curr Med Chem; 2011; 18(30):4674-83. PubMed ID: 21867480
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
3. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Yue W; Berstein L
Endocr Relat Cancer; 2003 Jun; 10(2):111-30. PubMed ID: 12790774
[TBL] [Abstract][Full Text] [Related]
4. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
8. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
Saha T; Makar S; Swetha R; Gutti G; Singh SK
Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
[TBL] [Abstract][Full Text] [Related]
9. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Sengupta S; Jordan VC
Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
[TBL] [Abstract][Full Text] [Related]
10. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer.
Xiong S; Song K; Xiang H; Luo G
Eur J Med Chem; 2024 Apr; 270():116393. PubMed ID: 38588626
[TBL] [Abstract][Full Text] [Related]
11. Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor.
Zeng L; Zielinska HA; Arshad A; Shield JP; Bahl A; Holly JM; Perks CM
Endocr Relat Cancer; 2016 Feb; 23(2):125-34. PubMed ID: 26647383
[TBL] [Abstract][Full Text] [Related]
12. Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
McDonnell DP; Wardell SE; Norris JD
J Med Chem; 2015 Jun; 58(12):4883-7. PubMed ID: 26039356
[TBL] [Abstract][Full Text] [Related]
13. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer.
Patani N; Martin LA
Mol Cell Endocrinol; 2014 Jan; 382(1):683-694. PubMed ID: 24121024
[TBL] [Abstract][Full Text] [Related]
14. Anabolic effect of the traditional Chinese medicine compound tanshinone IIA on myotube hypertrophy is mediated by estrogen receptor.
Zhao P; Soukup ST; Hegevoss J; Ngueu S; Kulling SE; Diel P
Planta Med; 2015 May; 81(7):578-85. PubMed ID: 26018796
[TBL] [Abstract][Full Text] [Related]
15. The silent estrogen receptor--can we make it speak?
Billam M; Witt AE; Davidson NE
Cancer Biol Ther; 2009 Mar; 8(6):485-96. PubMed ID: 19411863
[TBL] [Abstract][Full Text] [Related]
16. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
17. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
18. Cell proliferation and modulation of interaction of estrogen receptors with coregulators induced by ERα and ERβ agonists.
Evers NM; van den Berg JH; Wang S; Melchers D; Houtman R; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
J Steroid Biochem Mol Biol; 2014 Sep; 143():376-85. PubMed ID: 24923734
[TBL] [Abstract][Full Text] [Related]
19. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
20. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
